Tukysa (tucatinib) may represent a new patient-friendly option as a first line maintenance treatment possibility for patients ...
HER2CLIMB-05 trial evaluated Tukysa in combination with Herceptin and Perjeta for HER2-positive metastatic breast cancer, ...
Researchers have identified chromosomal instability in circulating tumour cells as a prognostic and predictive biomarker in ...
A potential option for patients who do not have access to neoadjuvant immunotherapy Triple negative breast cancer is an aggressive subtype of breast cancer marked by higher rates of relapse and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback